Vivek Gupta

NISM XV Certified.
No investment advice. For educational purposes only.

[Vivek Gupta @gupta_viv]

Already present in 15 states and has ambition to cover whole of India in a few years. Opportunity is huge.

[Vivek Gupta @gupta_viv]

Chandan Healthcare🧵
Changed business model-franchisees as collection centres to supplement own centres.
With 1,000 franchisees by end FY27 & 3,000 by FY29 franchisees will contribute a lot to sales- even Rs 1 lac p.m. per franchisee translates to 60crs in FY27 and 360cr in FY29

[Vivek Gupta @gupta_viv]

Franchisees will lead to higher utilisation of diagnostic centres - will lead to substantial increase in PAT margins.
Diagnostics is still largely an unorganised market in most of India - Chandan is capturing opportunity in tier 2 cities where larger players are not present.

[Vivek Gupta @gupta_viv]

Kwality Pharma
At current trailing PE of 47 it is still cheaper than peer pharma companies like Sakar Healthcare (PE>70). Kwality's forward PE is 17 (at expected FY 29 EPS of 225).

[Vivek Gupta @gupta_viv]

Kwality Pharma 🧵
AGM notes - Co reiterated points in investor concall:
1. Sales target of 700cr+ for FY27 and 1000cr+ for FY 29. Guidance may be revised upwards based on performance.
2. Hormone plant to be commissioned in Nov 2026. Sales to ROW through existing distributor chann

[Vivek Gupta @gupta_viv]

@sabarisec issued at discount to market price..

[Vivek Gupta @gupta_viv]

Kwality Pharma
Doesnt export to US so no impact of tariffs. Focusing on Europe & other regulated markets to improve margins.
Product mix improvement along with operational leverage (large volume growth) will improve margins
INR depreciation is tailwind which will increase margins

[Vivek Gupta @gupta_viv]

Kwality Pharma 🧵
AGM notes - Co reiterated points in investor concall:
1. Sales target of 700cr+ for FY27 and 1000cr+ for FY 29. Guidance may be revised upwards based on performance.
2. Hormone plant to be commissioned in Nov 2026. Sales to ROW through existing distributor chann

[Vivek Gupta @gupta_viv]

Chandan Healthcare
Conversion of warrants @ Rs 234 - almost a year before due date of conversion.

[Vivek Gupta @gupta_viv]

Chandan Healthcare 🧵
Quite east to spot this co is going to do well.
1. High growth diagnostic market
2. Leading player in UP & Uttrakhand. Presence in 15 states
3. Has adopted franchisee model - going to boost utilisation of capex heavy centres to achieve profitability quickly

[Vivek Gupta @gupta_viv]

@SSachinKMishra @AIEquityDesk @drprashantmish6 @nid_rockz @AimInvestments @Chart_Wallah108 @ValueEducator @InvestInMicro @soicfinance US is largest export mkt for co. Can tariffs impact business model.

[Vivek Gupta @gupta_viv]

@Niitesh16 Will hold KPL for at least 3 years.. this is the highest growth phase of company.. if they add more plants in future company can grow more..

[Vivek Gupta @gupta_viv]

Kwality Pharma 🧵
AGM notes - Co reiterated points in investor concall:
1. Sales target of 700cr+ for FY27 and 1000cr+ for FY 29. Guidance may be revised upwards based on performance.
2. Hormone plant to be commissioned in Nov 2026. Sales to ROW through existing distributor chann

[Vivek Gupta @gupta_viv]

@raghavwadhwa Kwality Pharma - For next 4 years Sales CAGR 35% and PAT CAGR 50%. Expected Sales in FY 30 - INR 1500 Cr at 30% margins implying PAT of INR 310 Cr (from current PAT of 67 Cr) translating into EPS of 300 (current EPS - 65). CMP is 3,300 at PE of 42.

[Vivek Gupta @gupta_viv]

@Niitesh16 If PE multiple remains at 40 then 5,000cr mcap is possible in FY 28 as EPS in FY 27 is expected to be 110. But if PE increases then possible in FY 27. I think if company revises guidance upwards then 5,000 is possible in FY27

[Vivek Gupta @gupta_viv]

New challenge for Renewable Energy sector
India proposes mandatory battery storage for new renewable projects from July 2027 https://t.co/W3EcS6JmB1

[Vivek Gupta @gupta_viv]

4. Exclusive tie-up with Jeena Sikho - earlier breakeven of centres. Jeeno Sikho's growth will translate into Chandan's growth
5. EBITDA Margins currently at 36% can go above 40% with increase in franchisee business which is >50% margin
6. Operating leverage is going to boost PAT

[Vivek Gupta @gupta_viv]

Chandan Healthcare 🧵
Quite east to spot this co is going to do well.
1. High growth diagnostic market
2. Leading player in UP & Uttrakhand. Presence in 15 states
3. Has adopted franchisee model - going to boost utilisation of capex heavy centres to achieve profitability quickly

[Vivek Gupta @gupta_viv]

Chandan Healthcare is undiscovered gem in the high growth Diagnostics space. With projected 50% topline growth every year at 40% margin, it is available at 11x expected FY 28 EPS of 20

[Vivek Gupta @gupta_viv]

6. Algeria JV to start by mid FY 2028
Company is confident of its growth plans and it seems they will revise guidance upwards in few quarters.

[Vivek Gupta @gupta_viv]

4. Second biologics (Keytruda generic) to be launched in Dec 2028 when patent expires. They have done sales tie-up for sales to hospitals in India
5. They will be doing third shift in General plant (Unit 1) to achieve 1,000 cr sales target. have already increase capacity by 20%.

[Vivek Gupta @gupta_viv]

Chandan Healthcare is undiscovered gem in the high growth Diagnostics space. With projected 50% topline growth every year at 40% margin, it is available at 11x expected FY 28 EPS of 20

[Vivek Gupta @gupta_viv]

Chandan Healthcare 🧵
Co's strategy has evolved from own-center led business to leveraging franchise network
*Sales: guidance of 50% growth p.a. for 3 years - 240cr in FY27, 350Cr in FY28, 800cr by FY30 (standalone- without pharmacy which has been sold)
How will this be achieved

[Vivek Gupta @gupta_viv]

Ratnaveer is up 2x from 133 to 260 since i started posting about the company...

[Vivek Gupta @gupta_viv]

Ratnaveer Precision Engineering
IPO in 2023 at Rs 98. (including OFS by promoter)
2026 - promoters buying through QIP at ~145. Institutional investors also participated in QIP.
Does it mean promoters made mistake by selling in IPO? Or fresh IPO infusion helped co grow much more